海思科：HSK39297片获新适应症临床试验批准

Core Viewpoint - The company has received approval from the National Medical Products Administration for clinical trials of its innovative drug HSK39297 for the treatment of generalized myasthenia gravis [1] Group 1 - HSK39297 is a new small molecule drug independently developed by the company [1] - Preclinical studies indicate that HSK39297 has a clear target, confirmed efficacy, and good safety profile [1] - The drug is expected to become an effective treatment for generalized myasthenia gravis [1]